← Back to Clinical Trials
Recruiting NCT07306468

NCT07306468 Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07306468
Status Recruiting
Phase
Sponsor Çankırı Karatekin University
Condition Schizophenia Disorder
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2025-11-01
Primary Completion 2026-11-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL
Interventions
Pulmonary Function TestRespiratory Muscle Strength EvaluationQuality of Life Assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2025-11-01 with a primary completion date of 2026-11-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational study aims to evaluate exercise capacity, pulmonary function, respiratory muscle strength, and quality of life in individuals diagnosed with schizophrenia and bipolar disorder. These psychiatric conditions are associated with sedentary lifestyles, metabolic side effects of psychotropic medications, and increased comorbidity risks, all of which may negatively impact physical fitness and respiratory health. By assessing cardiorespiratory endurance, pulmonary parameters (FVC, FEV₁), and respiratory muscle strength in this population, the study seeks to identify physiological limitations and contribute to the development of more effective rehabilitation strategies. The findings may support multidisciplinary approaches to improving physical health and overall quality of life in individuals with severe mental illness.

Eligibility Criteria

Inclusion Criteria: * Being volunteer for participation * Being 18 to 65 age Exclusion Criteria: * Having any respiratory, cardiac, neurologic or orthopedic disease which may affect respiratory functions or exercise capacity * Having any neuropsychiatric disease except schizophrenia or bipolar disorder

Contact & Investigator

Central Contact

Furkan Özdemir, PT, Ph.D.

✉ furkanozdemir@karatekin.edu.tr

📞 +905383264855

Frequently Asked Questions

Who can join the NCT07306468 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Schizophenia Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07306468 currently recruiting?

Yes, NCT07306468 is actively recruiting participants. Contact the research team at furkanozdemir@karatekin.edu.tr for enrollment information.

Where is the NCT07306468 trial being conducted?

This trial is being conducted at Çankırı, Turkey (Türkiye).

Who is sponsoring the NCT07306468 clinical trial?

NCT07306468 is sponsored by Çankırı Karatekin University. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology